Navigation Links
Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
Date:1/14/2011

SEATTLE, Jan. 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the pricing of a public offering of $540 million aggregate principal amount of 2.875% convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from its previously announced $500 million offering.  The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common Stock") or a combination of cash and shares of Common Stock, at Dendreon's election. Dendreon also granted the underwriter of the offering of the Notes an option to purchase up to an additional $80 million aggregate principal amount of Notes solely to cover overallotments.  The Notes will be the unsecured, senior obligations of Dendreon and will bear interest at a rate of 2.875% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2011.  The offering is expected to close on January 20, 2011, subject to customary closing conditions.

The conversion rate will initially equal 19.5160 shares of Common Stock per $1,000 principal amount of Notes, which corresponds to an initial conversion price of approximately $51.24 per share of Common Stock, representing a conversion premium of 40.00% over $36.60, which was the closing price per share of the Common Stock on January 13, 2011.  The conversion rate is subject to adjustment upon the occurrence of certain events.  

Dendreon estimates that its net proceeds from the offering of the Notes will be approximately $529.2 million (or approximately $607.6 million if the underwriter exercises its overallotment option in full) after deducting underwriting fees and without deducting estimated offering expenses that are payable by Dendreon.  Dendreon intends to use the
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... 29, 2015  HealthSouth Corporation (NYSE: ... of post-acute healthcare services, offering both facility-based and ... operations for the second quarter ended June 30, 2015. ... by strong volume growth in both segments and ... Jay Grinney, President and Chief Executive Officer of ...
(Date:7/29/2015)... -- Research and Markets ( ... "Global Biosimilars Market, 2015 - 2025" ... Biosimilars Market, 2015 - 2025, report provides an ... With the blockbuster biologics losing patent protection and ... being viewed as viable substitutes to the highly ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ( ... increased partnerships with VA and Military Medical centers ... Fiber Density (ENFD) and Sweat Gland Nerve Fiber ... neuropathy ( https://therapath.com/skin ). Demonstration ... Density (ENFD) on punch skin biopsy is a ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... (Nasdaq: PBIO ) ("PBI" or the "Company") today ... was $334,041 compared to $174,071 for the comparable period in ... PCT products and services was $233,256 for the three months ... period in 2007, a 97% increase. During the fourth ...
... 4 Tigris Pharmaceuticals, Inc., a privately held ... New Drug (IND) application for the Company,s geranylgeranyltransferase ... Food and Drug Administration. This will allow the ... the safety of GGTI-2418 during the first quarter ...
... Head of Nektar Therapeutic,s Pulmonary Business Unit, Among ... Savara, Inc., a biopharmaceutical company developing novel ... today announced that it has expanded its Board ... Elam, former head of the pulmonary business unit ...
Cached Biology Technology:Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Savara Expands Board of Directors, Appoints Three New Members 2Savara Expands Board of Directors, Appoints Three New Members 3
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... Ever wonder why that government clerk was so rude ... always doles out the most demeaning tasks? Or, on a ... and humiliated their prisoners? In a new study, ... have found that individuals in roles that possess power but ...
... (Sept. 20, 2011) -- A Rice University research team is ... to develop innovative new technologies that can significantly reduce greenhouse ... Coal- and natural-gas-fired power plants account for about half of ... year. For example, a 500-megawatt coal-fired power plant emits enough ...
... millipedes and worms, can help ensure the survival of ... from Cardiff University. Huge fungal networks, often stretching ... for space and resources and, now, findings have shown ... potential to govern the outcome of these battles. ...
Cached Biology News:Power corrupts, especially when it lacks status 2Power corrupts, especially when it lacks status 3Rice wins grant to develop CO2 capture technology 2Rice wins grant to develop CO2 capture technology 3Peacekeeping creatures help maintain woodland diversity 2
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
BlotGel application pool -see Blotters (Semi-Dry) for more info...
... This microscope is described by end-users ... it incorporates the fundamentals of light microscopy ... and small footprint, it does not require ... in a busy lab environment. The DM-BA300 ...
Request Info...
Biology Products: